

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**NOTICE OF 2024 ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN THAT** the 2024 annual general meeting (the “AGM”) of CanSino Biologics Inc. (the “Company”) will be held at 1:30 p.m. on Wednesday, June 4, 2025 at No. 1, Yuebin Hall, 2nd Floor, Hyatt Regency Tianjin East, No. 126 Weiguo Road, Hedong District, Tianjin, the PRC for the following purposes:

**ORDINARY RESOLUTIONS**

1. To consider and approve the working report of the Board of Directors for the year of 2024.
2. To consider and approve the working report of the Board of Supervisors for the year of 2024.
3. To consider and approve the annual report of the Group for the year of 2024 and its abstract.
4. To consider and approve the financial accounts report and financial audit report of the Group for the year of 2024.
5. To consider and approve the profit distribution plan of the Company for the year of 2024.
6. To consider and approve the re-appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the domestic auditor and internal control audit agency and the re-appointment of Deloitte Touche Tohmatsu as the international auditor of the Company for the year of 2025.
7. To consider and approve the proposed increase and/or renewal of bank credit line for the year of 2025.
8. To consider and approve the proposal on the uncovered deficit amounting to one-third of the total paid-up share capital of the Company.

9. To consider and approve the proposal on the adjustment to remuneration scheme of the non-executive Director(s).

### **SPECIAL RESOLUTIONS**

10. To consider and approve the proposed grant of general mandate to the Board to issue, allot and deal with additional A Shares and/or H Shares (including any sale or transfer of Treasury H Shares of the Company) or equivalent rights not exceeding 20% of the total number of Shares (excluding Treasury H Shares, if any) in issue as of the date of passing this proposed resolution for a period from the date of passing of this proposed resolution at the AGM until earliest of (i) the conclusion of the 2025 annual general meeting of the Company; (ii) the expiration of the period within which the 2025 annual general meeting of the Company is required by the Articles of Association or other applicable laws to be held; or (iii) the date of revocation or variation of the authority given under this proposal by a special resolution by the Shareholders at a general meeting, and to authorize the Board and its delegates (i) to make amendments to the Articles of Association as it thinks fit so as to reflect the new share capital structure upon the issue or allotment of additional shares of the Company pursuant to the General Mandate; and (ii) to execute and implement all such documents, do all such acts and things or take any steps in connection with and to give effect to the General Mandate to the extent permitted by applicable laws and regulations.
11. To consider and approve the proposed grant of the General Mandate under Simplified Procedure to the Board to issue A Shares, the total proceeds of which shall not exceed RMB300 million and not exceeding 20% of the net assets at the end of the most recent year during a period from the date of passing this proposed resolution at the AGM until the date of conclusion of the 2025 annual general meeting of the Company, and to authorize the Board and its delegates to approve, execute and do, or procure to be executed and done, all such documents, deeds and things as it may consider necessary in connection with the General Mandate under Simplified Procedure.
12. To consider and approve the proposed grant of the Repurchase Mandate to the Board to repurchase a total number of A Shares and/or H Shares not exceeding 10% of the total number of Shares (excluding Treasury H Shares, if any) in issue as of the date of passing this proposed resolution at the AGM, with its own funds during a period from the date of passing this proposed resolution at the AGM until earliest of (i) the conclusion of the 2025 annual general meeting of the Company; or (ii) the date of revocation or variation of the authority given under this proposed resolution by a special resolution by the Shareholders at a general meeting of the Company, and to authorize the Board and its delegates to execute and implement all such documents, do all such acts and things or take any steps in connection with and to give effect to the Repurchase Mandate to the extent permitted by applicable laws and regulations.

13. To consider and approve the proposed authorization for issue of onshore and offshore debt financing instruments.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, May 13, 2025

*Notes:*

- (1) Unless otherwise specified, the terms used in this notice should have the same meanings as those defined in the circular of the Company dated May 13, 2025.
- (2) All resolutions at the AGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Hong Kong Listing Rules. The results of the poll will be published on the websites of the Company at [www.cansinotech.com](http://www.cansinotech.com) and the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) after the AGM.
- (3) Any Shareholder entitled to attend and vote at the AGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a Shareholder.
- (4) In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H shares), at least 24 hours before the AGM (i.e. not later than 1:30 p.m. on Tuesday, June 3, 2025) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting at the AGM or any adjourned meeting thereof should he/she so wish.
- (5) For the purpose of determining the list of holders of H Shares who are entitled to attend the AGM, the H share register of members of the Company will be closed from Tuesday, June 3, 2025, to Wednesday, June 4, 2025, both days inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the AGM, unregistered holders of the shares shall ensure all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Monday, June 2, 2025 for registration.
- (6) In case of joint shareholders, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
- (7) Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.

- (8) A shareholder or his/her proxy should produce proof of identity when attending the AGM.
- (9) References to date and time in this notice are to Hong Kong dates and time.

*As of the date of this notice, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.*